Changing the Injection Burden in T2D With Weekly Insulin
Cara Orr, MS, MMS, PA-C
In this four-part Vital Rounds series, PA Orr explores once-weekly basal insulin and its potential to reduce injection burden for patients with type 2 diabetes. She reviews the barriers to insulin use, including needle phobia, mobility challenges, and the burden of daily injections, and introduces the two recently approved weekly options, insulin icodec and insulin efsitora alfa.
PA Orr then shares the clinical considerations behind choosing daily or weekly therapy, including drug interactions, hypoglycemia risk, and glucose monitoring. She also offers practical approaches to patient conversations about treatment expectations, injection routines, titration, and missed doses. The series concludes with a patient case that illustrates shared decision-making and follow-up during a transition from daily to weekly basal insulin.
Video 1: Type 2 Diabetes and Insulin Use
PA Orr reviews insulin’s role in type 2 diabetes management, common barriers to treatment, and how once-weekly basal insulin may help reduce injection burden.
Video 2: Clinical Considerations for Basal Insulin
PA Orr explores considerations for choosing daily or weekly basal insulin, including patient preferences, monitoring needs, hypoglycemia risk, and treatment access.
Video 3: Basal Insulin and Patient Conversations
In this video, PA Orr shares practical strategies for discussing treatment expectations, glucose monitoring, injection routines, and follow-up to help patients prepare for once-weekly basal insulin.
Video 4: A Case for Weekly Basal Insulin
Follow a patient case illustrating the transition from daily to weekly basal insulin, with attention to shared decision-making, lifestyle considerations, education, and monitoring.
Supported by
